Loading clinical trials...
Loading clinical trials...
A Phase Ib, Single- and Multiple-Dose, Open-Label Study of The Safety, Pharmacokinetics and Pharmacodynamics of Obinutuzumab in Adults With End-Stage Renal Disease and Hypersensitization Awaiting Renal Transplantation
Conditions
Interventions
Obinutuzumab
Intravenous Immunoglobulin
Locations
9
United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
UCSF
San Francisco, California, United States
Stanford Health Care
Stanford, California, United States
Johns Hopkins Hospital
Baltimore, Maryland, United States
Mayo Clinic - Minnesota
Rochester, Minnesota, United States
Mayo Clinic
Rochester, Minnesota, United States
Start Date
November 19, 2015
Primary Completion Date
November 26, 2018
Completion Date
November 26, 2018
Last Updated
January 29, 2020
NCT06314503
NCT06438445
NCT03640026
NCT05968391
NCT06288451
NCT03380962
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions